Fresenius Kabi continues the expansion of its biosimilars portfolio in the U.S. with the introduction of Conexxence (denosumab-bnht) and Bomyntra® (denosumab-bnht) in the United States.

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach ...

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol) ...

Fresenius announced that its operating company, Fresenius Kabi, has introduced two new biosimilars – Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) – in the United States. These denosumab ...

Alvotech, Kashiv, and Advanz Pharma report positive results for their biosimilar AVT23 compared to Xolair in clinical study.

Positive results from the confirmatory clinical efficacy and safety study of ADL-018, proposed biosimilar to XOLAIR® The clinical study met its primary endpoint in Chronic Spontaneous Urticaria ...

Alvotech and Advanz Pharma announce positive EMA opinion for AVT06, a biosimilar to Eylea®, advancing access for eye disorder treatments in Europe.